A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

NCT00863525 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: odanacatib
DRUG: Comparator: Placebo

Sponsor

Merck Sharp & Dohme LLC